FAT4 sirna

FAT4 siRNA (Human)

Cat. Num. AAA829203

• Gene Names: FAT4; FATJ; FAT-J; CDHF14; CDHR11; HKLLS2; VMLDS2; NBLA00548
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: FAT4; FAT4 siRNA (Human); CDHF14; FATJ; Protocadherin Fat 4; hFat4; Cadherin family member 14; FAT tumor suppressor homolog 4; Fat-like cadherin protein FAT-J; FAT4 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: FAT4 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 4982

• Applicable Applications for FAT4 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human FAT4 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for FAT4 sirna

siRNA to inhibit FAT4 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 603844373
• NCBI GeneID: 79633
• NCBI Accession #: NP_001278214.1
• NCBI GenBank Nucleotide #: NM_001291285.1
• UniProt Accession #: Q6V0I7; Q3LIA6; Q8TCK7; Q9H5T6; A8K5Z6; B5MDG4
• Molecular Weight: 542,616 Da
• NCBI Official Full Name: protocadherin Fat 4 isoform 2
• NCBI Official Synonym Full Names: FAT atypical cadherin 4
• NCBI Official Symbol: FAT4
• NCBI Official Synonym Symbols: FATJ; FAT-J; CDHF14; CDHR11; HKLLS2; VMLDS2; NBLA00548
• NCBI Protein Information: protocadherin Fat 4
• UniProt Protein Name: Protocadherin Fat 4
• Protein Family: Protocadherin
• UniProt Gene Name: FAT4
• UniProt Synonym Gene Names: CDHF14; FATJ; hFat4
• UniProt Entry Name: FAT4_HUMAN

NCBI Description

The protein encoded by this gene is a member of the protocadherin family. This gene may play a role in regulating planar cell polarity (PCP). Studies in mice suggest that loss of PCP signaling may cause cystic kidney disease, and mutations in this gene have been associated with Van Maldergem Syndrome 2. Alternatively spliced transcript variants have been noted for this gene. [provided by RefSeq, Mar 2014]

Uniprot Description

FAT4: May function in the regulation of planar cell polarity. Cadherins are cell-cell interaction molecules. 3 isoforms of the human protein are produced by alternative splicing.

Protein type: Cell adhesion; Membrane protein, integral

Chromosomal Location of Human Ortholog: 4q28.1

Cellular Component: apical part of cell; plasma membrane; integral to membrane

Molecular Function: protein binding; calcium ion binding

Biological Process: heart morphogenesis; heterophilic cell adhesion; inner ear receptor stereocilium organization and biogenesis; plasma membrane organization and biogenesis; neurogenesis; gut development; ureteric bud branching; cerebral cortex development; homophilic cell adhesion

Disease: Van Maldergem Syndrome 2; Hennekam Lymphangiectasia-lymphedema Syndrome 2